Liquidia Corporation (LQDA)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Liquidia Corporation May Have Engaged In Securities Fraud And Investors Are Urged To Join The Schall Law Firm's Investigation
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Inquiring Into Liquidia Corporation's Questionable Practices And Shareholders Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Liquidia Corporation Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - LQDA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Liquidia Corporation (LQDA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Corporation May Have Violated Securities Regulations And The Schall Law Firm Urges Investors To Partake In An Investigation
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LQDA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Liquidia Corporation Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
The Schall Law Firm Is Looking Into Whether Liquidia Corporation Engaged In Securities Fraud And Affected Shareholders Can Lend A Hand
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Liquidia Corporation Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - LQDA
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
